Docetaxel Trihydrate

證據等級: L5

預測適應症: 0 個

Docetaxel Trihydrate: Drug Repurposing Evaluation Report

One-Sentence Summary

Docetaxel trihydrate is a taxane-class antineoplastic agent widely used in the treatment of various solid tumours including breast cancer, non-small cell lung cancer, and prostate cancer. The TxGNN model did not generate any predicted new indications for this drug, and the evidence pack contains significant data gaps in regulatory details, safety information, and mechanism of action. No repurposing candidates are available for evaluation at this time.

Quick Overview

Item	Content
Original Indication	Antineoplastic (specific approved indication text unavailable)
Predicted New Indication	None — TxGNN returned no predictions
TxGNN Prediction Score	N/A
Evidence Level	L5 (No predictions or supporting studies)
Malaysia Market Status	✓ Marketed
Number of Registrations	5
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, the TxGNN model did not return any repurposing predictions for docetaxel trihydrate. This may be due to one or more of the following reasons:

Missing DrugBank ID mapping: The evidence pack does not contain a DrugBank ID for docetaxel trihydrate. Without a valid DrugBank ID, the drug cannot be mapped to nodes in the TxGNN knowledge graph, and therefore no predictions can be generated. Docetaxel’s DrugBank ID is known to be DB01248 — resolving this mapping gap should be the first remediation step.
Ingredient name form: The query used “DOCETAXEL TRIHYDRATE” (the hydrate salt form) rather than the INN “docetaxel”. Name normalisation may have failed to resolve this to the canonical form used in the knowledge graph.

Docetaxel is a semi-synthetic taxane that works by disrupting microtubule dynamics, inhibiting mitotic cell division. It binds to β-tubulin subunits of microtubules, stabilising them and preventing depolymerisation, which ultimately leads to cell cycle arrest at the G2/M phase and apoptosis. This well-characterised mechanism of action is broadly relevant across multiple solid tumour types, suggesting that repurposing predictions should be feasible once the data mapping issues are resolved.

Clinical Trial Evidence

Currently no predicted indications are available, therefore no targeted clinical trial search was performed.

To generate clinical trial evidence, the DrugBank ID mapping and TxGNN prediction pipeline must first be completed successfully.

Literature Evidence

Currently no predicted indications are available, therefore no targeted literature search was performed.

Malaysia Market Information

Authorization Number	Product Name	Dosage Form	Approved Indication
(Not available)	(Not available)	(Not available)	(Not available)
(Not available)	(Not available)	(Not available)	(Not available)
(Not available)	(Not available)	(Not available)	(Not available)
(Not available)	(Not available)	(Not available)	(Not available)
(Not available)	(Not available)	(Not available)	(Not available)

Note: 5 registrations were identified via NPRA query (2026-03-27), but detailed registration information (authorization numbers, product names, dosage forms, and approved indication text) was not populated in the evidence pack. This data gap must be remediated by querying the NPRA database directly.

Cytotoxicity

Docetaxel is a well-established cytotoxic antineoplastic agent (taxane class). The following information is based on known pharmacological properties:

Item	Content
Cytotoxicity Classification	Conventional cytotoxic (Taxane class — microtubule-stabilising agent)
Myelosuppression Risk	High — Neutropenia is the most common dose-limiting toxicity; febrile neutropenia risk is significant
Emetogenicity Classification	Low to moderate
Monitoring Items	CBC with differential (before each cycle), liver function tests (AST, ALT, bilirubin, ALP), renal function, fluid retention monitoring
Handling Protection	Must follow cytotoxic drug handling regulations — closed-system transfer devices recommended; protective gown, double gloves, and eye protection required during preparation and administration

Safety Considerations

Detailed safety data (key warnings, contraindications, and drug interactions) was not available in this evidence pack. Please refer to the package insert for complete safety information.

Known critical safety considerations for docetaxel (from general pharmacological knowledge):

Hepatic impairment: Docetaxel is contraindicated in patients with severe hepatic impairment (bilirubin > ULN, or AST/ALT > 1.5× ULN with ALP > 2.5× ULN)

Neutropenia: Patients should not receive docetaxel if neutrophil count < 1,500 cells/mm³

Hypersensitivity: Severe hypersensitivity reactions (including anaphylaxis) have been reported; premedication with corticosteroids is required

Fluid retention: Cumulative fluid retention can be severe; premedication regimen is essential

Conclusion and Next Steps

Decision: Hold

Rationale: The TxGNN model did not generate any repurposing predictions for docetaxel trihydrate, most likely due to a missing DrugBank ID mapping and/or ingredient name normalisation failure. Without predicted indications, no evidence assessment can be performed. The evidence pack also contains critical data gaps across regulatory details, safety information, and mechanism of action.

To proceed, the following is needed:

Resolve DrugBank ID mapping — Map “DOCETAXEL TRIHYDRATE” to DrugBank ID DB01248 (docetaxel) and re-run the prediction pipeline
Populate NPRA registration details — Query the Malaysia NPRA database to obtain authorization numbers, product names, dosage forms, and approved indication text for all 5 registrations
Obtain safety data — Download and parse the package insert(s) to extract key warnings, contraindications, and drug interaction information
Re-run TxGNN prediction — Once the DrugBank ID is resolved, execute both KG and DL prediction methods to generate repurposing candidates
Collect evidence — After predictions are available, query ClinicalTrials.gov, PubMed, and ICTRP for supporting evidence

Disclaimer: This report is for research purposes only and does not constitute medical advice. All drug repurposing candidates require clinical validation before application.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.